Comparative Analysis of Proteinuria and Longitudinal Outcomes in Immune Complex Membranoproliferative

Fernando Caravaca-Fontán1, Remedios Toledo-Rojas2, Ana Huerta3

  • 1Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain.

PubMed

Insights

Reducing proteinuria significantly improves kidney outcomes in C3 glomerulopathy (C3G) and immune complex-mediated glomerulonephritis (IC-MPGN). Achieving a 50% reduction in proteinuria is linked to a lower risk of kidney failure and slower decline in kidney function.

Area of Science:

  • Nephrology
  • Immunology
  • Internal Medicine

Background:

  • C3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) are rare kidney diseases with similar pathogenesis.
  • The prognostic value of proteinuria reduction in these conditions is not well understood.

Purpose of the Study:

  • To compare outcomes in C3G and IC-MPGN.
  • To assess how proteinuria reduction impacts kidney prognosis in these rare diseases.

Main Methods:

  • Retrospective, longitudinal, multicenter study of 149 patients with C3G or IC-MPGN.
  • Utilized linear mixed-effects models for proteinuria trajectories and Cox regression for kidney failure risk.
  • Calculated time-averaged proteinuria (TA-P) to evaluate its prognostic impact.

Main Results:

  • A 50% or greater reduction in proteinuria over time was associated with a significantly lower risk of kidney failure (HR: 0.61; 95% CI: 0.46-0.75).
  • Proteinuria reduction correlated with slower estimated glomerular filtration rate (eGFR) decline, with specific reductions at 6 and 12 months showing benefit.
  • Lower time-averaged proteinuria (< 1 g/d) predicted better kidney outcomes.

Conclusions:

  • Proteinuria reduction is a significant positive prognostic factor in both C3G and IC-MPGN.
  • Achieving substantial proteinuria reduction is associated with improved kidney survival and slower progression of kidney disease.
Abstract